α-Synuclein and tau, two targets for dementia

Matías Silva, Valentina Caro, Camila Guzmán, George Perry, Carlos Areche, Alberto Cornejo

Producción científica: Contribución a los tipos de informe/libroCapítulorevisión exhaustiva

11 Citas (Scopus)

Resumen

Older people are increasing in number worldwide and they are affected by neurodegenerative disorders. Tauopathies are neurodegenerative disorders that involve diseases such as progressive supranuclear palsy (PSP), frontotemporal dementia linked to chromosome 17 (FTD-17), corticobasal degeneration, and Alzheimer's disease (AD) among others. Other neurodegenerative disorders such as Parkinson's disease is characterized for inclusion denominated as Lewis bodies conformed by hyperphosphorylated alpha-synuclein protein (α-syn). However, there are some neurodegenerative disorders that overlap each other such as dementia with Lewy bodies (DLB), Lewy body variant of AD and Parkinson's disease with dementia (PDD). Moreover, there is an increase in the number of patients of PD with dementia and patients with AD with Lewy body's inclusions in post mortem samples. Thus, we find pertinent to discuss both covalent and noncovalent inhibitors targeting alpha-synuclein and tau.

Idioma originalInglés
Título de la publicación alojadaStudies in Natural Products Chemistry
EditorialElsevier Science B.V.
Páginas1-25
Número de páginas25
DOI
EstadoPublicada - 2021

Serie de la publicación

NombreStudies in Natural Products Chemistry
Volumen67
ISSN (versión impresa)1572-5995

Áreas temáticas de ASJC Scopus

  • Descubrimiento de medicamentos
  • Química orgánica

Huella

Profundice en los temas de investigación de 'α-Synuclein and tau, two targets for dementia'. En conjunto forman una huella única.

Citar esto